Modern Healthcare - - News Makers -

Julie Ger­berd­ing,

the for­mer di­rec­tor of the Cen­ters for Dis­ease Con­trol and Preven­tion, has been named pres­i­dent of Merck Vaccines, ef­fec­tive Jan. 25. In her new role, Ger­berd­ing, 54, will lead the com­pany’s $5 bil­lion global vac­cine busi­ness, which mar­kets pe­di­atric, ado­les­cent and adult vaccines and pro­vides vaccines in coun­tries world­wide. Ger­berd­ing re­places Margie McG­lynn, who re­tired from Merck Nov. 1, 2009, ac­cord­ing to a com­pany spokesman. Ger­berd­ing will over­see the com­mer­cial­iza­tion of the cur­rent port­fo­lio of vaccines, plan for the in­tro­duc­tion of vaccines from the com­pany’s pipe­line, and quicken the com­pany’s ef­forts to broaden ac­cess to its vaccines in de­vel­op­ing coun­tries. Ger­berd­ing served as di­rec­tor at the CDC from 2002 un­til 2009, where she led the HHS agency dur­ing more than 40 emer­gency-re­sponse ini­tia­tives for health crises, in­clud­ing an­thrax bioter­ror­ism, food-borne dis­ease out­breaks and nat­u­ral dis­as­ters. She also ad­vised gov­ern­ments in other coun­tries about pub­lic health is­sues such as SARS, AIDS and obe­sity.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.